First Time Loading...

Oncotelic Therapeutics Inc
OTC:OTLC

Watchlist Manager
Oncotelic Therapeutics Inc Logo
Oncotelic Therapeutics Inc
OTC:OTLC
Watchlist
Price: 0.036 USD -8.86%
Updated: Mar 28, 2024

Intrinsic Value

OTLC doesn't have a meaningful market cap.

Oncotelic Therapeutics, Inc. is a biopharmaceutical company. [ Read More ]

The intrinsic value of one OTLC stock under the Base Case scenario is 0.016 USD. Compared to the current market price of 0.036 USD, Oncotelic Therapeutics Inc is Overvalued by 56%.

Key Points:
OTLC Intrinsic Value
Base Case
0.016 USD
Overvaluation 56%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Oncotelic Therapeutics Inc

Backtest OTLC Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling OTLC stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Oncotelic Therapeutics Inc's business.

What risks and challenges
does Oncotelic Therapeutics Inc face in the near future?

Summarize the latest earnings report
of Oncotelic Therapeutics Inc.

Provide P/E
for Oncotelic Therapeutics Inc and its competitors.

Financials

Balance Sheet Decomposition
Oncotelic Therapeutics Inc

Current Assets 365.5k
Cash & Short-Term Investments 268k
Receivables 19k
Other Current Assets 78.5k
Non-Current Assets 29.7m
Long-Term Investments 22.6m
Intangibles 7.1m
Current Liabilities 17.1m
Accounts Payable 2m
Accrued Liabilities 772.2k
Short-Term Debt 9.7m
Other Current Liabilities 4.7m
Non-Current Liabilities 435.6k
Long-Term Debt 899.1k
Other Non-Current Liabilities -463.5k
Efficiency

Earnings Waterfall
Oncotelic Therapeutics Inc

Revenue
70k USD
Operating Expenses
-975.5k USD
Operating Income
-905.5k USD
Other Expenses
-11.6m USD
Net Income
-12.5m USD

Free Cash Flow Analysis
Oncotelic Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

OTLC Profitability Score
Profitability Due Diligence

Oncotelic Therapeutics Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

18/100
Profitability
Score

Oncotelic Therapeutics Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

OTLC Solvency Score
Solvency Due Diligence

Oncotelic Therapeutics Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Positive Net Debt
Short-Term Solvency
18/100
Solvency
Score

Oncotelic Therapeutics Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OTLC Price Targets Summary
Oncotelic Therapeutics Inc

There are no price targets for OTLC.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

OTLC Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

OTLC Price
Oncotelic Therapeutics Inc

1M 1M
-10%
6M 6M
+20%
1Y 1Y
-28%
3Y 3Y
-86%
5Y 5Y
-70%
10Y 10Y
-99%
Annual Price Range
0.036
52w Low
0.02
52w High
0.05
Price Metrics
Average Annual Return -7.51%
Standard Deviation of Annual Returns 55.19%
Max Drawdown -95%
Shares Statistics
Market Capitalization 14.3m USD
Shares Outstanding 399 184 000
Percentage of Shares Shorted 2.5%

OTLC Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Oncotelic Therapeutics Inc Logo
Oncotelic Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

14.3m USD

Dividend Yield

0%

Description

Oncotelic Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Agoura Hills, California and currently employs 16 full-time employees. The firm is engaged in the development of ribonucleic acid (RNA) therapeutics as well as small molecule drugs against cancer and infectious diseases. The Company’s pipeline includes ArtiVeda/ArtiShield, OT-101, CA4P and Oxi4503. ArtiVeda/ArtiShield is a natural derivative from the plant Artemisia. Artemisinin derivatives are used to treat malaria. OT-101 is antisense against TGF-2 for the treatment of solid tumors with focus on brain cancer in adults and diffuse intrinsic pontine glioma (DIPG) in children. OT-101 is antisense against TGF-2 for the treatment of various viruses, including the SARS and the COVID-19, on its own and in conjunction with other compounds. CA4P is a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma. Oxi4503 is VDA for the treatment of liquid tumors with focus on childhood leukemia.

Contact

CALIFORNIA
Agoura Hills
29397 Agoura Road Suite 107
+16506357000.0
https://www.oncotelic.com/

IPO

1993-08-26

Employees

16

Officers

Chairman & CEO
Dr. Vuong Trieu Ph.D.
Chief Financial Officer
Mr. Amit Shah
Chief Clinical Officer of Translational Medicine & Director
Dr. Anthony E. Maida III, B.A., MA, MBA, Ph.D.
CBO & GM of AI Division
Mr. Saranjit Saund
Consultant & Director
Mr. Steven W. King
Chief Scientific Officer
Dr. Larn Hwang
Show More
Chief Medical Officer
Dr. Seymour Howard Fein M.D.
CTO of AI Division
Mr. Burcak Beser
Show Less

See Also

Discover More
What is the Intrinsic Value of one OTLC stock?

The intrinsic value of one OTLC stock under the Base Case scenario is 0.016 USD.

Is OTLC stock undervalued or overvalued?

Compared to the current market price of 0.036 USD, Oncotelic Therapeutics Inc is Overvalued by 56%.